Management

Bo Rode Hansen

President & Chief Executive Officer

Education: MSc, Ph.D., MBA

Background: President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Other ongoing assignments: Advisor for Novo Seeds

Scandion Oncology shares and warrants
40,400 shares and 1,071,688 warrants


Maj Hedtjärn

Chief Operating Officer and Head of R&D Operations 

Education: MSc, PhD.

Background: Dr. Maj Hedtjärn has held numerous leadership positions within R&D in biotech and pharma (Roche, Santaris Pharma and Lundbeck), most recently as VP, Head of Drug Discovery, RNA Therapeutics Research at Roche. Maj has extensive experience in drug discovery & development, program leadership, building portfolios across different disease areas, big pharma partnerships, alliance management, executive leadership and developing and implementing scientific and business strategies.

Other ongoing assignments: Scientific Advisor for Lipigon Pharmaceuticals AB

Scandion Oncology shares and warrants
16,000 shares (owned via Venilia Holding ApS)


Johnny Stilou

Chief Financial Officer

Education: MSc in Business Economics and Auditing, Executive Management Program, INSEAD.

Background: Johnny Stilou has held numerous Executive positions as Chief Financial Officer within biotech and pharma. Most recently as CFO at Amgen Research Copenhagen and Nuevolution AB (acquired by Amgen). Previously he was CFO at Veloxis Pharmaceuticals (acquired by Asahi Kasei).

Other ongoing assignments: None

Scandion Oncology shares and warrants
10,000 shares


Jan Stenvang

Chief Technology Officer 

Education: MSc, PhD.

Background: Co-founder of Scandion Oncology. Associate Professor at the University of Copenhagen since 2013. Researcher at the Danish Cancer Society concerning gene regulation and anti-estrogen-resistant breast cancer. Jan has authored 89 publications, most of which relate to translational cancer research, biomarkers and drug resistance.

Other ongoing assignments: Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.

Scandion Oncology shares and warrants
1,371,519 shares


Peter Michael Vestlev

Chief Medical Officer

Education: MD, CBA, MPP

Background: Chief Physician, Oncologist, Region Zealand and Capital Region Previously, Head of Radiotherapy unit, Herlev Hospital, Head of Cooperating Cancer Departments, Head of research unit Roskilde Hospital, consultant for the Danish Medicines Agency, Chief Oncologist Capital Region.

Other ongoing assignments: External lecturer at Roskilde University. Consultant Region Zealand department of oncology.

Scandion Oncology shares and warrants
154,300 shares and 53,584 warrants


Nicklas Lindland Roest

Chief Regulatory Officer 

Education: MSc. Pharm.

Background: Project manager and regulatory/CMC specialist within the pharmaceutical and biotech industry.

Other ongoing assignments: None

Scandion Oncology shares and warrants
34,188 shares and 53,585 warrants (Partly owned via Lindland Roest Holding ApS)


Annie Rasmussen

Chief Clinical Officer 

Education: RN, Master of Public Health

Background: Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982.

Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operations Oncology Venture A/S. Founder of Health- CreationDK and CancerGuidesDK.

Other ongoing assignments: Board Member of North Star Group A/S.

Scandion Oncology shares and warrants
18,795 shares and 53,585 warrants


Mads Aaboe Jensen

VP, Business Development and Innovation

Education: MSc, PhD

Background: Business development, search & evaluation and R&D in biotech and pharma.

Other ongoing assignments: None

Scandion Oncology shares and warrants
11,000 shares

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance. 

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.